Literature DB >> 14586275

Evidence against the fecal-oral route of transmission for Helicobacter pylori infection in childhood.

Selma Yegane Tosun1, Erhun Kasirga, Pelin Ertan, Selahattin Aksu.   

Abstract

BACKGROUND: Acquisition of Helicobacter pylori (H. pylori) occurs mainly in childhood. However, little is known about the mode of transmission. In such developing countries as Turkey, where the hygienic situation facilitates the transmission of hepatitis A virus (HAV), infection with HAV is mainly transmitted via the enteral route. Therefore, it seemed advisable to evaluate the role of fecal-oral transmission in the spread of H. pylori. MATERIAL/
METHODS: Blood samples taken from healthy children (n= 90) 2-16 years old were studied for anti-H. pylori and anti-hepatitis A antibodies by enzyme immunoassay.
RESULTS: Of the 90 children, 33.3% were seropositive for both H. pylori and HAV, 33.3% were seronegative for both, 8.9 % were seropositive for H. pylori only, and 24.4% were seropositive for HAV only. The percentage of seropositive children increased with age for H. pylori and HAV. There was no significant relationship in seroprevalence between H. pylori and HAV when analyzed by logistic regression analysis (p=0.178).
CONCLUSIONS: This study suggests that the seropositivity rates of H. pylori and HAV increase with age, while the fecal-oral route may not be an important mode of transmission for H. pylori in children living in western Anatolia, in the Manisa region.

Entities:  

Mesh:

Year:  2003        PMID: 14586275

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  2 in total

Review 1.  Helicobacter pylori Infection in the general population: A Middle Eastern perspective.

Authors:  Hossein Khedmat; Reza Karbasi-Afshar; Shahram Agah; Saeed Taheri
Journal:  Caspian J Intern Med       Date:  2013

2.  Serologic Evidence for Fecal-Oral Transmission of Helicobacter pylori.

Authors:  David Bui; Heidi E Brown; Robin B Harris; Eyal Oren
Journal:  Am J Trop Med Hyg       Date:  2015-11-23       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.